SWOG clinical trial number
CTSU/EAA171
Optimizing Prolonged Treatment In Myeloma Using MRD Assessment (OPTIMUM)
Open
Abbreviated Title
Optimizing Prolonged Treatment In Myeloma Using MRD Assessment (OPTIMUM)
Research committees
Myeloma
Treatment
CC-5013 (Lenalidomide)
Ixazomib
Eligibility Criteria Expand/Collapse
Eligibility Criteria: SWOG has endorsed this study through the Cancer Trials Support Unit (CTSU) of the National Cancer Institute.
Please contact CTSU directly by phone (888/823-5923) or on the CTSU website (http://ctsu.org) for more information and registration procedures.
Please contact CTSU directly by phone (888/823-5923) or on the CTSU website (http://ctsu.org) for more information and registration procedures.
Other Clinical Trials
SWOG Clinical Trial Number
S2213
A Phase III, Randomized Study of Daratumumab, Cyclophosphamide, Bortezomib and Dexamethasone (Dara-VCD) Induction Followed by Autologous Stem Cell Transplant or Dara-VCD Consolidation and Daratumumab Maintenance in Patients with Newly Diagnosed AL Amyloidosis
Research Committee(s)
Myeloma
Activated
12/01/2023
Accrual
1%
Open
Phase
SWOG Clinical Trial Number
S2209
A Phase III Randomized Trial for Newly Diagnosed Multiple Myeloma Patients Considered Frail or Ineligible for Stem Cell Transplant Comparing Frontline Regimen Bortezomib-Lenalidomide-Dexamethasone-Lite (VRd-Lite) with Daratumumab-Lenalidomide-Dexamethasone (DRd) Followed by Len+/-Dara (R+/-D) Maintenance
Research Committee(s)
Myeloma
Activated
05/30/2023
Accrual
10%
Open
Phase
SWOG Clinical Trial Number
S2005
A PHASE II RANDOMIZED STUDY COMPARING IBRUTINIB AND RITUXIMAB VS. VENETOCLAX AND RITUXIMAB IN PREVIOUSLY UNTREATED WALDENSTROM'S MACROGLOBULINEMIA (WM) /LYMPHOPLASMACYTIC LYMPHOMA (LPL)
Research Committee(s)
Myeloma
Activated
06/24/2021
Accrual
10%
Open
Phase